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The small heat-shock protein of 27 kDa (HSP27) is highly expressed in
many cancers and is associated with aggressive tumour behaviour, metasta-
sis, poor prognosis and resistance to chemotherapy. We aimed at assessing
the role of HSP27 in modulating responses to target therapies. We selected
several oncogene-addicted cancer cell lines, which undergo either cell cycle
blockade or cell death in response to agents that target the specific onco-
gene. Surprisingly, HSP27 suppression alone resulted in the apoptotic
death of MET-addicted EBC-1 lung cancer cells, epidermal growth factor
receptor (EGFR)-addicted colorectal carcinoma (CRC) DiFi cells and
BRAF-addicted CRC COLO205 and OXCO-1 and melanoma COLO741
cells, all of which also undergo death when treated with the specific tar-
geted agent. In other cell lines, such as MET-addicted gastric carcinoma
MKN45 and EGFR-addicted CRC SW48 lines, where oncogene inhibition
only blocked proliferation, HSP27 knockdown made targeted agents switch
from cytostatic to cytotoxic activity. Mechanistically, the more the cells
were susceptible to HSP27 suppression, the more they were primed for
death, as demonstrated by increased levels of mitochondrial outer mem-
brane permeabilization. Priming for death was accompanied by the
increase in pro-apoptotic proteins of the BCL2 family and of active
caspase-3 and lamin B. Together, these data suggest that oncogene-
addicted cells require HSP27 for survival and that HSP27 might interfere
with the effectiveness of targeted agents.
1. Introduction
The most successful current paradigms in targeted
therapy consist of directly inhibiting mutated or ampli-
fied oncogenes, to which the cancer cells, but not the
normal cell counterpart, are ‘addicted’. Depriving the
addicted cancer cell of this signal leads to cell death or
at least growth arrest. In human cancer treatment, the
most convincing evidence came out, supporting the
concept of ‘oncogene addiction’, as there are examples
of the therapeutic efficacy of antibodies or drugs tar-
geting specific oncogenes.
Among known oncogenes, those encoding kinases
account for a significant number of molecular targets
exploited today in the clinic. Their targeting agents
might be small-molecule inhibitors, which block kinase
enzymatic activity or signalling (for a review, see
Gross et al., 2015). For example, the inhibition of the
activated BRAF oncogene with small molecules repre-
sents an important therapeutic approach. The V600
BRAF mutation is the most common in melanoma,
and mutation-specific inhibitors are effectively used to
treat melanoma and some of the nonmelanoma can-
cers with the same mutation (Hyman et al., 2015).
Abbreviations
EGFR, epidermal growth factor receptor; HSP27, heat-shock protein of 27 kDa; MOMP, mitochondrial outer membrane permeabilization.
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When oncogenic kinases are receptors, monoclonal
antibodies can be used that bind to the extracellular
region of the receptor and interfere at varying levels
with its activity (for a review, see Weiner, 2015). Mon-
oclonal antibodies interfering with the signalling of the
hepatocyte growth factor receptor encoded by the
MET oncogene and of the epidermal growth factor
receptor (EGFR) encoded by the HER1 gene have
received approval for the treatment of various types of
cancers. Drugging the RAS oncogene, a small GTPase,
came out to be by far more difficult, although of para-
mount importance, RAS being among the most com-
mon oncogenic drivers in human malignancies.
Activating RAS mutations are associated with approx-
imately 30% of human cancers that are frequently
resistant to standard therapies. The addiction of these
cancers to RAS activation has been studied. A better
understanding of RAS structure, biochemistry, pro-
cessing and signalling will open new possibilities to
overcome RAS-driven tumours. Recently, efforts to
develop direct inhibitors of RAS have gathered new
momentum (for reviews, see Cox et al., 2014; Ostrem
and Shokat, 2016; Singh et al., 2015).
The small heat-shock proteins (sHSPs) are molecular
chaperones that play a role in development, stress
responses and diseases, including cancer (Lanneau
et al., 2010; Zoubeidi and Gleave, 2012). The small
heat-shock protein of 27 kDa (HSP27) encoded by the
HSPB1 gene shows anti-aggregation property, as it
participates in sequestering damaged proteins (Garrido
et al., 2012) and is involved in the proteasomal degra-
dation of proteins under stress conditions (Lanneau
et al., 2010). HSP27 also exerts important anti-apopto-
tic function by binding apoptotic proteins (for a
review, see Acunzo et al., 2012). Clinically, HSP27 is
highly expressed in many cancers including breast
(Conroy et al., 1998), ovarian (Arts et al., 1999), pros-
tate (Cornford et al., 2000) and others (Bruey et al.,
2000) and is associated with aggressive tumour beha-
viour, metastasis and poor prognosis. HSP27 increases
during the early phase of stem cell differentiation
(Mehlen et al., 1997), and thus, it might play a role in
sustaining cancer stem cell growth and survival. It is
noteworthy that HSP27 suppression alone resulted in
the death of prostate (Zoubeidi et al., 2007) and pan-
creatic carcinoma cells (Baylot et al., 2011). Moreover,
HSP27 inhibition increases the efficacy of the
chemotherapeutic agents such as gemcitabine (Baylot
et al., 2011), paclitaxel (Andrieu et al., 2010; Pavlıkova
et al., 2015) and doxorubicin (Dıaz-Chavez et al.,
2013). However, in pancreatic cancer a recent conflict-
ing report associates an increased phosphorylation of
HSP27 with better prognosis (Okuno et al., 2016).
Hence, HSP27 might play important roles in cancer
onset and progression and in its response to treatment.
We (Musiani et al., 2014) and others (Lelj-Garolla
et al., 2015) have shown that targeted agents might
upregulate HSP27 expression weakening the efficacy of
inhibitors.
Here, we show that HSP27 might impair the efficacy
of targeted agents in many contexts of oncogene addic-
tion through its role in protecting cells from mitochon-
drial priming.
2. Materials and methods
2.1. Cell lines and reagents
Most cell lines used were purchased from the American
Type Culture Collection (ATCC) after 2011, unless
otherwise specified. All colorectal carcinoma (CRC) cell
lines used were kindly provided by Professor Alberto
Bardelli, Department of Oncology, University of Tor-
ino, Italy. DiFi and OXCO-1 cell lines were a generous
gift from Dr J. Baselga in November 2004 (Oncology
Department of Vall d’Hebron University Hospital, Bar-
celona, Spain) and Dr V. Cerundolo in March 2010
(Weatherall Institute of Molecular Medicine, University
of Oxford, UK), respectively. All cell lines were cultured
as suggested by the provider. JNJ-38877605 was
obtained from Janssen Pharmaceutical (Johnson &
Johnson, New Brunswick, NJ, USA). Cetuximab (CTX)
was purchased from Merck KGaA (Darmstadt, Ger-
many). PLX4720 was obtained from Selleck Chemicals.
2.2. Quantitative PCR
Quantitative PCR was carried out as described previ-
ously (Bardella et al., 2007). Total cellular RNA was
isolated using the SV Total RNA Isolation kit (Pro-
mega, Fitchburg, WI, USA). To quantify the expression
levels of HSP27-encoding gene, equal amounts of
cDNA were synthesized using the Moloney murine leu-
kaemia reverse transcriptase (Promega) and mixed with
SsoFast EvaGreen Supermix (Bio-Rad, Hercules, CA,
USA) and 300 lM of each of the respective forward and
reverse primers. Quantitative real-time PCR was per-
formed on a MyiQ thermal cycler (Bio-Rad). Target
gene expression was evaluated using a relative quantifi-
cation approach, with POLR2A (GenBank accession
no. NM000937.4) as an internal reference. Primer sets
used are as follows: POLR2A: forward TG-CAAGG
GCAAAAACATATGC, reverse AGCTCTAGGCC
A-GAACGCC; HSP27: forward GCGTGTCCC
TGGATGTCAAC, reverse TGTATTTCCGCGTGA
AGCAC. PCR cycling conditions were as follows: 30 s
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at 95 °C 30, 5 s at 95 °C plus 15 s at 60 °C (40 cycles),
30 s at 95 °C, and 10 s at 65 °C plus 10 s at 0.5 °C (60
cycles: melting curve).
2.3. Western blot analysis
Western blot analysis was carried out as described pre-
viously (Musiani et al., 2014) using the following anti-
bodies: mouse monoclonal anti-vinculin from Sigma-
Aldrich (St. Louis, MO, USA); mouse monoclonal
anti-HSP27 and mouse monoclonal anti-ERK and
anti-P-ERK (Thr202/Tyr204) from Cell Signaling
Technology (Beverly, MA, USA); and mouse mono-
clonal anti-KRAS from Santa Cruz Biotechnology
(Santa Cruz, CA, USA).
2.4. RNA interference
Transient silencing of HSP27 by RNA interference
was performed using On-TargetPlus SmartPool (Dhar-
macon, Lafayette, CO, USA). In each experiment, the
On-TargetPlus nontargeting pool (Dharmacon) was
used as the negative control. The cell lines were plated
at 30–40% confluency and transfected with the indi-
cated siRNA pools (100 nM) using oligofectamine
(Invitrogen, Eugene, OR, USA), according to the man-
ufacturer’s instructions. Stable silencing of HSP27 was
achieved using specific shRNAs transduced into the
cells by means of lentiviral vectors. HSP27-specific
shRNAs (TRCN0000008753 and TRCN0000342857)
were obtained from the Sigma-Aldrich TRC lentiviral
shRNA library (Sigma-Aldrich). Transient silencing of
KRAS was achieved as described (Lamba et al., 2014).
2.5. Cell transduction with lentiviral vectors
Cells were transduced using second-generation lentivi-
ral vectors, whose stocks were produced by transient
transfection of 293T cells with the packaging plasmid
pCMV-DR8.74, the envelope plasmid pMD2G-V
respective transfer gene-carrying vector. Serial dilu-
tions of freshly harvested conditioned medium were
used to infect cells in a six-well plate in the presence of
polybrene (8 lgmL1).
2.6. Apoptosis and viability assays
Apoptosis was measured as staining with APC-conju-
gated annexin V (Bender MedSystems, Burlingame, CA,
USA) and DAPI (Invitrogen), in accordance with the
manufacturer’s instructions. The samples were analysed
on CyAn-ADP flow cytometer (Dako, Carpinteria, CA,
USA). Data acquisition was performed using SUMMIT
software (Dako). To assess growth inhibition, a viability
assay was used, seeding cells at density optimized for
96-well plates. The cells were cultured in the presence of
drugs or vehicle and subjected to the CellTiter-Glo lumi-
nescent cell viability assay (Promega) in at least tripli-
cate samples according to the manufacturer’s
specifications. The results are an average of three inde-
pendent assays. Apoptosis and growth inhibition shown
were always measured in parallel experiments.
2.7. Immunoassay of apoptotic proteins
Human pro- and anti-apoptotic proteins were mea-
sured using the Bio-Plex Multiplex Immunoassays
(Bio-Rad Laboratories, Hercules, CA, USA) based on
the Luminex technology (Luminex, Austin, TX, USA)
and carried out at Bioclarma srl, Torino, Italy. Briefly,
the assay combines the principle of a sandwich
immunoassay with fluorescent bead-based technology,
thus allowing individual and multiplex analysis of dif-
ferent analytes in a single test tube (Vignali, 2000).
Capture antibodies directed against the desired bio-
marker are covalently coupled to fluorescently dyed
magnetic microspheres, each with a distinct colour
code or spectral address to allow identification of indi-
vidual proteins within a multiplex suspension. A
biotinylated detection antibody is added to create a
sandwich complex. The final detection complex is
formed with the addition of streptavidin–phycoery-
thrin (SA-PE) conjugate and measured with the Bio-
Plex 100 System array reader (Bio-Rad Laboratories),
which identifies and quantifies each specific reaction
based on bead colour and fluorescent signal intensity.
Data were processed using BIO-PLEX MANAGER software
(version 6.1) (Bio-Rad Laboratories) using five-
parametric curve fitting and converted in ngmL1.
2.8. Mitochondrial outer membrane potential
For the flow cytometric evaluation of mitochondrial
membrane potential (Dwm), cells were stained with the
fluorescent lipophilic cationic dye JC-1 (5,50,6,60-tetra-
chloro-1,10,3,30-tetraethyl-imidacarbocyanine iodide;
Sigma-Aldrich). JC-1 possesses the unique ability to dif-
ferentially label mitochondria with low and high mem-
brane potential (Dwm). In mitochondria with high
(Dwm), JC-1 forms multimeric aggregates that emit
orange–red light (wavelength of 590 nm) when excited
at 488 nm. In mitochondria with low (Dwm), JC-1 forms
monomers that emit green light (525–530 nm) when
excited at 488 nm. For labelling with JC-1, cells were
collected and incubated for 20 min with 1 lgmL1 of
JC-1 in culture medium at 37 °C in the dark. Cells were
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centrifuged to remove the supernatant. Cell pellets were
suspended in PBS, and the ratio of red/green fluores-
cence intensity was determined by flow cytometry. For
each sample, 10 000 events were recorded at a flow rate
of 200–300 cellss1, and debris and aggregates were
gated out by establishing a region around the popula-
tion of interest in the forward scatter/side scatter dot
plot on a log scale. Compensation between FL1 and
FL2 was carefully adjusted according to the manufac-
turer’s instructions. Green and orange–red fluorescences
were measured in FL-1 and FL-2 channel, respectively.
The samples were analysed on CyAn-ADP flow cytome-
ter (Dako). Data acquisition was performed using Sum-
mit software (Dako).
3. Results
3.1. MET oncogene-addicted carcinoma cells are
susceptible to HSP27 suppression
HSP27 silencing was alone able to commit the EBC-1
lung carcinoma cells to death (Figs 1A and S1A).
These cells display MET gene amplification and are
addicted to the MET oncogene activation as shown by
the induction of cell death by the selective MET kinase
inhibitor JNJ-38877605 (Fig. 1A). Cell death was fur-
ther increased when the MET inhibitor was adminis-
tered to HSP27-silenced cells (Fig. 1A). In line, HSP27
overexpression (Fig. S1B) protected EBC-1 cells from
JNJ-38877605 (Fig. 1B).
The MKN45 cells are known as MET-addicted cells as
inhibition of this kinase resulted in cell cycle arrest (Ber-
totti et al., 2009; Musiani et al., 2014). These cells were
not affected by HSP27 silencing alone (Figs 1C and
S1C). However, in HSP27-silenced cells the MET inhibi-
tor JNJ-38877605 induced cell apoptotic death (Fig. 1C),
although HSP27 expression is increased by the treatment
with the inhibitor (Musiani et al., 2014). Altogether,
these data show that in MET-addicted carcinoma cell
lines, HSP27 silencing affected cell survival and allowed
MET inhibitor to exert a full cytotoxic effect.
3.2. EGFR-addicted carcinoma cells are
susceptible to HSP27 suppression
HSP27 silencing was alone able to induce the apop-
totic death of the CRC-derived DiFi cells (Figs 2A
and S2A), which are addicted to EGFR because of
receptor amplification. These cells were susceptible to
anti-EGFR antibody cetuximab (CTX), which was
alone able not only to block proliferation (Medico
et al., 2015; Musiani et al., 2014) but also to affect cell
survival (Fig. 2A). HSP27 silencing further increased
the susceptibility of DiFi cells to CTX (Fig. 2A).
The CRC-derived SW48 cells are also classified as
EGFR-addicted because CTX was alone able to block
Fig. 1. Protection from apoptosis of MET-addicted cancer cell lines by HSP27. The indicated cell lines were transduced to express either
the shHSP27 or control scrambled sh (shCTRL) (A,C) or either the HSP27 cDNA or the corresponding empty vector (B). Silenced cells were
examined 72 h after transduction. (A) The HSP27-silenced EBC-1 lung cancer cells were treated with the MET inhibitor JNJ-38877605 for
further 48 h at the indicated concentrations; (B) HSP27-overexpressing EBC-1 cells were treated with the MET inhibitor JNJ-38877605 for
further 48 h at the indicated concentrations; (C) the HSP27-silenced MKN45 gastric cancer cells were treated with the MET inhibitor JNJ-
38877605 for further 48 h at the indicated concentrations. Apoptotic cells were measured using FACS analysis of AnnV and DAPI staining.
Significance was calculated using the one-way ANOVA performed using GRAPHPAD PRISM (GraphPad Software, San Diego, CA, USA):
*P < 0.05; **P < 0.001.
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cell proliferation (Musiani et al., 2014; Troiani et al.,
2014), as also shown in Fig. 2B. However, CTX was
not able to drive cells to death (Fig. 2C). HSP27
silencing (Fig. S2B) alone affected the survival of
SW48 cells and sensitized them to the EGFR inhibitor
so that the combined treatments resulted in increased
cell death (Fig. 2C), although HSP27 expression is
upregulated by the treatment with the inhibitor
(Musiani et al., 2014). Interestingly, no correlation
(Fig. S3) was found between the addiction to cetux-
imab and basal level of expression of HSP27 in 150
colorectal cancer cell lines treated with the drug, as
reported by Medico et al. (2015). Altogether, these
data show that in EGFR-addicted carcinoma cell lines,
HSP27 silencing affected cell survival and allowed the
EGFR inhibitor to exert a full cytotoxic effect.
3.3. BRAF-addicted carcinoma cells are
susceptible to HSP27 suppression
The BRAF-mutated COLO205 and OXCO-1 CRC cells
and the COLO741 melanoma cells display impaired
proliferation when treated with BRAF inhibitor
vemurafenib (Prahallad et al., 2012). Figure 3A shows
that the BRAF inhibitor PLX4720, the structurally clo-
sely related precursor of vemurafenib, similarly affected
the proliferation of these cell lines. Also the survival of
these cell lines was impaired by the BRAF inhibitor
(Fig. 3B–D). In all three cell lines, HSP27 knockdown
(Fig. S4) resulted in some degree of apoptotic death,
which was achieved fully after the treatment of silenced
cells with the BRAF inhibitor (Fig. 3B–D), although
BRAF inhibitor treatment induced an increase in the
HSP27 expression (Fig. S4). Altogether, these data
show that the BRAF-addicted cells are susceptible to
HSP27 silencing and fully committed to death by the
combined HSP27 silencing and BRAF inhibition.
3.4. RAS-addicted cells are susceptible to HSP27
suppression
HSP27 expression was knocked down in two CRC cell
lines (LS513 and SW837; Fig. S5), carrying two differ-
ent KRAS mutations (G12D and G12C, respectively).
These cell lines were previously described (Lamba
et al., 2014) as either addicted (LS513) or not addicted
Fig. 2. Protection from apoptosis of EGFR-addicted cancer cell lines by HSP27. The indicated CRC cell lines were transduced to express
either the shHSP27 or control scrambled sh (shCTRL). Silenced cells were examined 72 h after transduction. (A) DiFi cells were treated
with the EGFR antibody cetuximab (CTX, 5 nM for further 48 h); apoptotic cells were measured using FACS analysis of AnnV and DAPI
staining. (B) SW-48 cells were treated with the EGFR antibody cetuximab (CTX) at 5 nM for further 48 h, and cell growth was evaluated
with the CellTiter-Glo assay; (C) SW-48 cells were treated with the EGFR antibody cetuximab (CTX) at 5 nM for further 48 h, and apoptotic
cells were measured as in (A). Significance was calculated using the one-way ANOVA performed using GRAPHPAD PRISM: *P < 0.05;
**P < 0.001; ***P < 0.0005.
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(SW837) to the KRAS-activated pathway. In LS513
cells, either KRAS or HSP27 suppression reduced cell
proliferation (Fig. 4A), but neither was alone able to
commit cells to death (Fig. 4B). Conversely, the com-
bination further reduced cell proliferation (Fig. 4A)
and was effective in driving cell to death (Fig. 4B).
The SW837 cells were almost unaffected by KRAS
suppression and also by the combination of KRAS
and HSP27 silencing (Fig. 4C,D).
3.5. HSP27 suppression results in the modulation
of apoptosis-associated proteins and
mitochondrial priming
As it has been reported that HSP27 might protect
cells by binding proteins of the BCL2 family, first we
studied the proteins of this family with either pro- or
anti-apoptotic function in the MET-addicted MKN45
cells after HSP27 stable silencing. These cells were
studied first because, as described above (Fig. 1),
MKN45 cells (i) were not affected by HSP27 silencing
alone; (ii) did not die but no longer proliferated when
treated with MET inhibitor; and (iii) were driven to
apoptosis when the MET inhibitor was added to
HSP27-silenced cells.
We previously showed (Musiani et al., 2014) that
the pro-apoptotic BIM protein increased when MET-
addicted cells were treated with the MET inhibitor but
was not affected by HSP27 silencing; conversely, the
anti-apoptotic MCL1 protein decreased as a result of
the combination of HSP27 silencing and MET inhibi-
tion. Further screening of anti-BCL2 family proteins
with the antibodies of the Bio-Plex assay showed
(Fig. 5A,B) that MET inhibition in HSP27-silenced
MKN45 cells also resulted in the increase in the BAK
and BAX proteins and in active caspase-3 and lamin
B. Conversely, in these cells, where HSP27 silencing
alone did not result in cell death, accordingly pro- and
anti-apoptotic proteins were almost unaffected by the
HSP27 silencing alone.
Fig. 3. Protection from apoptosis of BRAF-addicted cancer cell lines by HSP27. (A) Proliferation of the CRC COLO205 and OXCO-1 cell lines
and of the melanoma COLO741 cell line, evaluated using CellTiter-Glo assay after cell plate treatment for 48 h with the indicated
concentrations of the BRAF inhibitor PLX4720. (B–D) The indicated cell lines were transduced to express either the shHSP27 or control
scrambled sh (shCTRL). Apoptosis of the same cell lines 72 h after cell transduction and treated, where indicated, with PLX4720 (1 lM) for
further 48 h. Apoptotic cells were measured using FACS analysis of AnnV and DAPI staining. Significance was calculated using the one-way
ANOVA performed using GRAPHPAD PRISM: *P < 0.05; **P < 0.001; ***P < 0.0005.
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Pro- or anti-apoptotic proteins were then analysed
using the Bio-Plex assay in the BRAF-addicted
OXCO-1, COLO741 and COLO205 cells. Figure S6A
shows the high basal level of BAX and BAK in
OXCO-1 and COLO741 cells, respectively, in line with
their propensity to death. The effect of HSP27 silenc-
ing onto pro- and anti-apoptotic proteins in these cell
lines, which undergo dramatic apoptosis when silenced
(Fig. 3B,C), was barely detected because of massive
cell death. A modest increase in BAK was detectable
in the COLO205 cells mostly after the treatment with
the targeted agent (Fig. S6B), and only the increase in
active caspase 3 was measured in all cell lines
(Fig. S6C).
As the net balance of pro- and anti-apoptotic pro-
teins results in the formation of mitochondrial pores
and possibly in the consequent decrease in mitochon-
drial outer membrane permeabilization (MOMP), we
measured MOMP using the cationic dye JC-1. JC-1
exhibits potential-dependent accumulation in mito-
chondria, indicated by fluorescence emission shift from
red to green, and can be quantified using flow cytome-
try (Szilagyi et al., 2006). MOMP decrease results in
proximity of cells to apoptosis threshold, a phe-
nomenon called priming. Figure 6A shows that in
MKN45 cells, in line with data of Fig. 1, there is a
correspondence between priming and cell death.
HSP27 silencing and the MET inhibitor alone did
not change priming and survival (green and blue
diamonds), while the combined treatment with HSP27
siRNAs and MET inhibitor resulted in increased prim-
ing and switching the effect of the MET inhibitor
towards cell death (red diamonds).
Then, we measured priming of all the other studied
cells and found that a basal level of priming in
COLO205 cells and to a lesser extent in OXCO-1 cells
(Fig. 6B) in line with their propensity to respond to
the targeted agent anti-BRAF drug (Fig. 3). In all but
MKN45 cells, HSP27 silencing alone increased priming
to death (Fig. 6B). Conversely, the treatment of cells
with control siRNA and the relevant targeted agent
resulted in a modest increase in mitochondrial priming
(Fig. S7).
As different level of basal and HSP27 silencing-
induced priming appeared correlated with the effects
on cell death shown in Figs 1–3, we measured in par-
allel priming and cell death in the same cell lines fol-
lowing silencing of HSP27 with siRNAs. As shown in
Fig. 6C, we found a correlation between cell death
and priming caused by HSP27 silencing.
4. Discussion
This study shows that HSP27 protects oncogene-
addicted cancer cells from the activation of the mito-
chondrial pathway of apoptosis, measured as increased
MOMP and increased levels of pro-apoptotic effector
proteins. These parameters define mitochondrial
Fig. 4. Protection from apoptosis of CRC cell lines addicted to KRAS by HSP27. Where indicated, either KRAS or HSP27 was silenced using
small interfering RNA pools. Nontargeting pool was expressed as control (siCTRL). (A) LS513 cells were transfected to express the
indicated siRNA for 72 h, and cell growth was evaluated using trypan blue exclusion assay. (B) The same cells were transfected as in (A),
and apoptosis was measured using FACS analysis of AnnV and DAPI staining. (C) The SW837 cells were transfected and cell growth was
evaluated as in (A). (D) The same cells were transfected and apoptosis measured as in (B). Significance was calculated using the one-way
ANOVA performed using GRAPHPAD PRISM: *P < 0.05; **P < 0.001; ns: not significant.
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readiness to trigger apoptosis, the so-called mitochon-
drial priming to death. This pathway is likely to be
often intrinsically active in oncogene-addicted cells,
likely because of oncogene overactivation. Moreover,
targeted agents can activate the same pathway, and we
show here that HSP27 silencing made cells more sus-
ceptible to these agents. The protective role of HSP27
makes cells surviving, and the net effect might be the
interference of HSP27 with targeted therapies. This is
important as HSP27 expression is increased in several
cancer histotypes (for a review, see Garrido et al.,
2006). Moreover, we had shown previously that
HSP27 expression is increased by cell treatment with
targeted agents through the activation of the HSF1
and HIF1a pathway (Musiani et al., 2014).
We show that cancer cells more susceptible to tar-
geted therapy, such as the colorectal BRAF-addicted
COLO205, which undergo cell death when treated with
the specific targeted agent, might even show a basal
level of mitochondrial priming, as well as cancer cells
more susceptible to chemotherapy (Ni Chonghaile
et al., 2011), and are consistently susceptible to the
loss of HSP27 which causes increased MOMP. MOMP
has been considered a point of no return in the apop-
totic programme for a long time. Conversely, our data
as well as other authors’ data (for a review, see Tait
and Green, 2010) show that cancer cells propagated in
culture can resist MOMP. It has been proposed that
the ability of cells to survive chronic MOMP depends
on a few mitochondria that evade permeabilization
Fig. 5. Evaluation of the expression of apoptosis-related proteins in MKN45 cells where HSP27 was silenced as in panel (C) of Fig. 1 versus
the expression in cell transduced with shCTRL. Cells were treated with JNJ-38877605 (50 nM for 36 h) where indicated. (A) Pro-apoptotic
proteins and (B) anti-apoptotic proteins were measured using Bio-Plex assay.
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Fig. 6. Mitochondrial priming of oncogene-addicted cancer cell lines was correlated with propensity to apoptotic death induced by HSP27
silencing. The percentage of cells showing mitochondrial priming to death, that is increased MOMP, was calculated by measuring
accumulation of JC-1 green monomers with FACS analysis. Where indicated, cells were transfected with either HSP27-specific (siHSP27) or
control small interfering RNA (siCTRL). (A) Plot showing the correlation in treated MKN45 cells between the percentage of cells showing
MOMP increase (primed) and that of cells showing annexin V and DAPI staining (apoptotic), measured with FACS analysis. The MET
inhibitor JNJ-605 was added 72 h after transfection, and cells were examined after 48 h. (B) Basal level of priming and levels achieved after
HSP27 suppression in the indicated cell lines. Significance was calculated using the one-way ANOVA performed using GRAPHPAD PRISM:
*P < 0.05; **P < 0.001. (C) Plot showing the correlation between level of cell priming and readiness to apoptosis in cells where HSP27
was silenced. Each diamond represents one experiment in which priming and apoptosis were measured in the same cells. In all the cell
lines of panel (B), the percentage of cells showing MOMP increase (primed) and that of cells showing annexin V and DAPI staining
(apoptotic) after HSP27 silencing were measured in at least three separate experiments.
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and repopulate the cell (Tait et al., 2010). Moreover, it
has been recently also shown that a limited level of
MOMP might be not only present and compatible
with life of cancer cells, but could even contribute in
promoting oncogenesis by enabling DNA damage
(Ichim et al., 2015; Liu et al., 2015).
MOMP and mitochondrial priming depends on the
balance between anti- and pro-apoptotic proteins of
the BCL2 family (Certo et al., 2006; Chipuk et al.,
2010), which are expressed at different level in differ-
ent tissues and cell types (Placzek et al., 2010). Among
these proteins, the effector proteins BAX and BAK
undergo oligomerization when activated, form pores in
the mitochondrial outer membrane and finally cause
apoptosis (Kluck et al., 1997; Wei et al., 2001). The
effector BAK and BAX can be activated by the BH3-
only proteins BIM and BID, also known as activators
(Sarosiek et al., 2013). Both effectors and activators
can be inhibited by the anti-apoptotic members of the
family (Certo et al., 2006). Induction of apoptosis
through BCL2 protein is a critical component of effec-
tive targeted therapies (Hata et al., 2015). It has been
previously demonstrated that in particular, BIM
increase is invariably associated with the targeting of
different oncogenic kinases that results in the down-
modulation of MEK–ERK and PI3K–AKT pathways
(for a review, see Hata et al., 2015). We already
reported BIM increase in response to the MET tyro-
sine kinase inhibitor and a decreased level of the anti-
apoptotic MCL1 after the silencing of HSP27 (Musiani
et al., 2014). This is in line with the report that MCL1
down-modulation is required for the full activity of
targeted inhibitors of the pathways activated by onco-
genic tyrosine kinase receptors, for example by those
of HER family (Faber et al., 2009; Misale et al.,
2015). We show here that MET inhibition in HSP27-
silenced cells was also associated with the increase in
BAK and BAX proteins, whose increased levels have
been correlated with better responses of cancer cells to
chemotherapy (Lange et al., 2003; Lindner et al., 2013;
Luo et al., 2015). These data confirm that drugs tar-
geting BCL2 proteins are promising allies of targeted
agents to eradicate tumours (for a review, see Hata
et al., 2015).
Silencing of HSP27 turned the antiproliferative
effect of targeted inhibitors into full cytotoxic activity.
Experiments demonstrated that HSP27 loss weakened
the anti-apoptotic machinery of the MET-addicted
cells. As mentioned above, not only BAX and BAK
proteins increased, but also the pro-apoptotic BIM
increased and the anti-apoptotic MCL1 decreased
(Musiani et al., 2014). This implies that the combina-
tion of HSP27 silencing and MET kinase inhibition
could more steadily control the growth of MET-
addicted tumours and suggests that a similar mecha-
nism drives full cytotoxicity driven by HSP27 silencing
and targeted agents.
HSP27 might protect cells from mitochondrial
apoptosis at several levels (for a review, see Acunzo
et al., 2012). For example, numerous studies report
that the caspase cascade inactivation is a consequence
of HSP27 binding with caspase-3 and cytochrome c
release from the mitochondria. Here, we show how-
ever that the protective effect might occur also earlier
in the mitochondrial pathway of apoptosis, by block-
ing mitochondrial permeabilization. This could be due
to the known ability of HSP27 to stabilize directly or
indirectly upstream molecules such as AKT and BAX
(Arrigo, 2007; Havasi et al., 2008; Zhang et al.,
2015).
5. Conclusions
The protective role of HSP27 makes cells surviving,
and the net effect might be the interference of HSP27
with targeted therapies. Thus, agents targeting HSP27
such as OGX-427 (Baylot et al., 2011; Matsui et al.,
2009), which is already undergoing clinical trials, and
aptamers (Gibert et al., 2011), could be envisaged as a
therapeutic approach to sensitize cells to targeted
agents.
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